ClinicalTrials.gg
CompletedNCT03837743Updated Sep 2, 2022Results posted

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

A Phase 2 interventional study of DUR-928 Topical Solution and Vehicle Topical Solution in Plaque Psoriasis, sponsored by Durect. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Psoriasis by Bausch Health Companies Inc. — 1 open to participants now, 4 under way, none of them phase 3. Psoriasis · Bausch Health Companies Inc..

Enrollment
21st of 23
25 · median 154
Started
2019
with 2 others
Phase 2
7 of 26
none open now
Registered
22nd of 26
by date

Among the 26 studies in Psoriasis by Bausch Health Companies Inc., this one is the 21st largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 22nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 26 studies in Psoriasis by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psoriasis by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in subjects with plaque psoriasis. Subjects will be instructed (randomly assigned) to apply DUR-928 solution to a target lesion on one arm and vehicle solution to a target lesion on the opposite arm once daily for up to four weeks. Subjects will occlude the treated areas for approximately two hours after each application.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or non-pregnant female 18 years of age or older.
  2. Subject has provided written .
  3. Subject has a clinical diagnosis of stable mild to moderate plaque psoriasis for at least two months.
  4. Females must be , surgically sterile, or use an effective method of . Women of (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 2/Baseline.
  5. Males (or their female partner) must agree to use an effective method of birth control throughout the study.
  6. Subject has two similar contralateral Target Plaques.
  7. Subject is willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
  8. Subject, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation of the plaque psoriasis or exposes the subject to an unacceptable risk by study participation.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
  3. Subject has guttate, pustular, erythrodermic, inverse, or other non-plaque forms of psoriasis.
  4. Subject has psoriasis beyond the two Target Plaques that, in the investigator's opinion, could not be reasonably managed with only a bland emollient during the study.
  5. Subject is currently enrolled in an drug or device study.
  6. Subject has been previously enrolled in this study and treated with test article.

Other protocol-defined inclusion and exclusion criteria assessed by the study staff may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    DUR-928 Topical Solution

    DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.

    Drug: DUR-928 Topical Solution

  • Placebo comparator
    Vehicle Topical Solution

    Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.

    Drug: Vehicle Topical Solution

Interventions

  • Topical solution containing active drug

  • DrugVehicle Topical Solution

    Topical solution containing no active drug

06

What researchers measure

Primary outcomes

  1. The Change From Baseline as Assessed on the Investigator's Global Assessment (IGA) Score.

    The IGA of the Target Plaques will be determined on a 5-point scale. 0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe

    Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)

Secondary outcomes

  1. The Change From Baseline as Assessed on the Clinical Signs of Psoriasis (Plaque Elevation, Scaling, and Erythema)

    Each clinical sign (plaque elevation, scaling, erythema) will be graded on a 5-point scale.0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe.

    Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)

  2. The Change From Baseline as Assessed on the Local Psoriasis Severity Index (LPSI)

    The LPSI is a sum of all three parameters (sum range of 0-12, with 12 being a worse outcome). Three parameters are plaque elevation, scaling, and erythema, each rated 0-4, 0=clear to 4=severe.

    Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)

  3. The Change From Baseline as Assessed by the Target Plaque Area.

    The surface areas of Target Plaque A (plaque on left arm) and Target Plaque B (plaque on right arm) will be measured.

    Time frame: Up to Day 57 (assessed at Baseline, and Weeks 2,4,8, change from baseline to week 4 and 8 reported)

  4. The Change From Baseline as Assessed on the Itch Numeric Rating Scale (I-NRS) for Pruritus.

    The I-NRS score is based on an 11-point scale where 0 represents "no itching" and 10 represents "worst itch imaginable."

    Time frame: Up to Day 57 (assessed at Baseline, and Weeks 2,4,8, change from baseline to week 4 and 8 reported)

Other outcomes

  1. The Change From Baseline as Assessed on the Target Plaque Comparison

    The Target Plaque Comparison is scored on a 3-point scale: 1A = Target Plaque A is better than Target Plaque B, 0 = Target Plaque A is the same as Target Plaque B, and 1B = Target Plaque A is worse than Target Plaque B.

    Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)

07

Results

Posted Sep 2, 2022

Participant flow

This was a multi-site study conducted at five sites in the United States of America. Date first subject enrolled: March 20, 2019 and date last subject completed: November 7, 2019.

Participant flow — Overall Study
MilestoneDUR-928 Topical Solution and Vehicle Topical Solution
Started25
Dur-928 topical solution lesion25
Vehicle topical solution lesion25
Completed22
Not completed3
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryThe Change From Baseline as Assessed on the Investigator's Global Assessment (IGA) Score.

The IGA of the Target Plaques will be determined on a 5-point scale. 0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe

Time frame:
Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
Reported as:
Mean · score on a scale
The Change From Baseline as Assessed on the Investigator's Global Assessment (IGA) Score.
score on a scaleDUR-928 Topical SolutionVehicle Topical Solution
Week 4 (change from baseline)-0.8 ± 0.83-1.0 ± 0.93
Week 8 (change from baseline)-0.6 ± 1.00-0.8 ± 1.10
Statistical analysis
  • DUR-928 Topical Solution vs Vehicle Topical Solution · Paired t-test · p = 0.022 · Mean difference (final values): 0.2
  • DUR-928 Topical Solution vs Vehicle Topical Solution · Paired t-test · p = 0.296 · Mean difference (final values): 0.2
SecondaryThe Change From Baseline as Assessed on the Clinical Signs of Psoriasis (Plaque Elevation, Scaling, and Erythema)

Each clinical sign (plaque elevation, scaling, erythema) will be graded on a 5-point scale.0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe.

Time frame:
Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
Reported as:
Mean · score on a scale
The Change From Baseline as Assessed on the Clinical Signs of Psoriasis (Plaque Elevation, Scaling, and Erythema)
score on a scaleDUR-928 Topical SolutionVehicle Topical Solution
Week 4 (Clinical Signs of Psoriasis - Plaque Elevation-Change from Baseline)-1.0 ± 0.88-1.2 ± 0.94
Week 8 (Clinical Signs of Psoriasis - Plaque Elevation-Change from Baseline)-0.7 ± 0.98-0.9 ± 1.06
Week 4 (Clinical Signs of Psoriasis - scaling-Change from Baseline)-0.8 ± 0.89-1.1 ± 1.06
Week 8 (Clinical Signs of Psoriasis - scaling-Change from Baseline)-0.6 ± 0.95-0.8 ± 1.18
Week 4 (Clinical Signs of Psoriasis - erythema-Change from Baseline)-1.0 ± 0.88-1.1 ± 1.00
Week 8 (Clinical Signs of Psoriasis - erythema-Change from Baseline)-0.9 ± 0.97-1.1 ± 0.97
SecondaryThe Change From Baseline as Assessed on the Local Psoriasis Severity Index (LPSI)

The LPSI is a sum of all three parameters (sum range of 0-12, with 12 being a worse outcome). Three parameters are plaque elevation, scaling, and erythema, each rated 0-4, 0=clear to 4=severe.

Time frame:
Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
Reported as:
Mean · score on a scale
The Change From Baseline as Assessed on the Local Psoriasis Severity Index (LPSI)
score on a scaleDUR-928 Topical SolutionVehicle Topical Solution
week 4 (change from Baseline)-2.7 ± 2.40-3.4 ± 2.76
week 8 (change from Baseline)-2.3 ± 2.69-2.8 ± 3.05
SecondaryThe Change From Baseline as Assessed by the Target Plaque Area.

The surface areas of Target Plaque A (plaque on left arm) and Target Plaque B (plaque on right arm) will be measured.

Time frame:
Up to Day 57 (assessed at Baseline, and Weeks 2,4,8, change from baseline to week 4 and 8 reported)
Reported as:
Mean · cm^2
The Change From Baseline as Assessed by the Target Plaque Area.
cm^2DUR-928 Topical SolutionVehicle Topical Solution
Week 4 (change from Baseline)-2.5 ± 11.02-7.4 ± 10.88
Week 8 (change from Baseline)-5.8 ± 10.26-8.3 ± 7.85
SecondaryThe Change From Baseline as Assessed on the Itch Numeric Rating Scale (I-NRS) for Pruritus.

The I-NRS score is based on an 11-point scale where 0 represents "no itching" and 10 represents "worst itch imaginable."

Time frame:
Up to Day 57 (assessed at Baseline, and Weeks 2,4,8, change from baseline to week 4 and 8 reported)
Reported as:
Mean · units on a scale
The Change From Baseline as Assessed on the Itch Numeric Rating Scale (I-NRS) for Pruritus.
units on a scaleDUR-928 Topical SolutionVehicle Topical Solution
Week 4 (change from baseline)-1.7 ± 2.19-1.7 ± 1.84
Week 8 (change from baseline)-1.6 ± 2.34-1.5 ± 2.11
Other pre-specifiedThe Change From Baseline as Assessed on the Target Plaque Comparison

The Target Plaque Comparison is scored on a 3-point scale: 1A = Target Plaque A is better than Target Plaque B, 0 = Target Plaque A is the same as Target Plaque B, and 1B = Target Plaque A is worse than Target Plaque B.

Time frame:
Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
Reported as:
Number · participants
The Change From Baseline as Assessed on the Target Plaque Comparison
participantsDUR-928 Topical Solution and Vehicle Topical Solution
Week 4 : Active Better2
Week 4 : Same13
Week 4 : Active Worse8
Week 8 : Active Better3
Week 8 : Same11
Week 8 : Active Worse8

Adverse events

Collected over Up to Day 57. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DUR-928 Topical Solution and Vehicle Topical Solution, Safety Population0/25 (0%)0/25 (0%)11/25 (44%)
DUR-928 Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site.0/25 (0%)0/25 (0%)4/25 (16%)
Vehicle Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site.0/25 (0%)0/25 (0%)3/25 (12%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDUR-928 Topical Solution and Vehicle Topical Solution, Safety PopulationDUR-928 Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site.Vehicle Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site.
DiarrhoeaGastrointestinal disorders1/25——
Application site erythemaGeneral disorders1/251/251/25
Application site fissureGeneral disorders1/251/251/25
Application site haemorrhageGeneral disorders1/251/251/25
Application site injuryGeneral disorders1/251/250/25
Application site painGeneral disorders1/251/251/25
Application site pruritusGeneral disorders1/251/251/25
Ear infectionInfections and infestations1/25——
Ligament sprainInjury, poisoning and procedural complications1/25——
Blood urineInvestigations1/25——

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)DUR-928 Topical Solution and Vehicle Topical Solution
Mean46.2 ± 11.32
Sex: Female, Male
Sex: Female, Male(Participants)DUR-928 Topical Solution and Vehicle Topical Solution
Female10
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DUR-928 Topical Solution and Vehicle Topical Solution
Hispanic or Latino6
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DUR-928 Topical Solution and Vehicle Topical Solution
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White22
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)DUR-928 Topical Solution and Vehicle Topical Solution
United States25
08

Study locations

5 sites
  • Site 01
    San Diego, California 92123, United States
  • Site 04
    Miami, Florida 33162, United States
  • Site 05
    Tampa, Florida 33609, United States
  • Site 02
    Plainfield, Indiana 46168, United States
  • Site 03
    Spokane, Washington 99202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Nov 2019, 8 months.

Results were first posted in Sep 2022, 2 years 9 months after primary completion. A results delay was requested in May 2020.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2019
First posted
Feb 12, 2019
StartActual
Feb 21, 2019
Primary completionActual
Nov 11, 2019
CompletionActual
May 20, 2020
Results delay requested
May 28, 2020
Results first posted
Sep 2, 2022
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03837743
Lead sponsor
Durect
Collaborators
Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Feb 21, 2019
Primary completion
Nov 11, 2019
Completion
May 20, 2020
Results posted
Sep 2, 2022
Last update
Sep 2, 2022

Study contacts

Tony Andrasfay
study director · Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larsucosterol

Start the discussion